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Pharmacokinetics Of Linezolid During Extracorporeal Membrane Oxygenation
Sir,
The extracorporeal membrane oxygenation (ECMO) is increasingly used in the critical setting for patients with respiratory failure and there is a growing body of knowledge describing the associated variations in plasma concentrations of drugs, including antibiotics, due to drug adsorption on the different components of the ECMO circuit. Currently, a multicentre study is ongoing to confirm if the standard antibiotic dosing in adult patients may still be considered appropriate [1] . Linezolid (LNZ) is extensively used in patients with pneumonia in critical care because of its strong activity against Staphylococcus aureus and its high pulmonary penetration, but there are no data on LNZ pharmacokinetics during ECMO [2] . Here we report the main pharmacokinetic parameters in three critically ill patients on ECMO treated with LNZ. Pharmacokinetic data were studied using Kinetica software (Thermo Scientific, Waltham, MA) and AUC 0-24 was calculated as AUC 0-24 = 2  AUC 0-12 [3] . In Table 1 the main LNZ pharmacokinetic parameters are reported, such as C max , C min , AUC 0-24 , half-life (t 1/2 ), clearance (CL), time above the MIC (t > MIC) and volume of distribution (V d ); we also reported in Table 1 
